Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00472992 · ClinicalTrials.gov registry record

Pregnancy Exposure Registry for Tysabri®

A clinical trial of Multiple Sclerosis and Pregnancy, sponsored by Biogen.

Completed
Registry status
376
Enrollment target
1
Study location

NCT00472992: Completed study of Multiple Sclerosis and Pregnancy, sponsored by Biogen.

NCT00472992 is a study of Multiple Sclerosis and Pregnancy that has completed, run by Biogen. The registered enrollment target is 376 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00472992, a study of Multiple Sclerosis and Pregnancy, has completed, sponsored by Biogen.

COMPLETED
Registry status
376 participants
Enrollment target
1
Study location

Study Summary

The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last Menstrual Period (LMP) or during pregnancy.

Study Locations (1)

West Virginia

  • United BioSource Corporation - Morgantown

Trial Details

FieldValue
Enrollment Target 376 participants
Start Date 2007-01
Est. Completion 2012-07
Biogen

334 total trials

What the finished NCT00472992 record still lists

NCT00472992 is an observational study that tracks outcomes without assigning an intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (36% lower).

The record links to 4 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT00472992 reports a single indexed study location in West Virginia.

Frequently Asked Questions

What is clinical trial NCT00472992 about?

NCT00472992 is a clinical study titled "Pregnancy Exposure Registry for Tysabri®". The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last Menstrual Period (LMP) or during pregnancy.

What is the current status of trial NCT00472992?

This trial is currently completed. The enrollment target is 376 participants. The study started on 2007-01. Estimated completion is 2012-07.

What conditions does trial NCT00472992 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Pregnancy, Crohn's Disease, Prenatal Exposure.

Who is sponsoring clinical trial NCT00472992?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00472992 being conducted?

This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00472992's enrollment target sits among peer trials

376 51st of 315 higher than 265 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03102125 · 376 participants · Phase 4

    Allograft Dysfunction in Heart Transplant

  • NCT05055297 · 376 participants · NA

    SELUTION4BTK Trial

  • NCT05912647 · 376 participants · NA

    Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes

  • NCT05963971 · 376 participants · NA

    A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00472992, the US trial registry maintained by the National Library of Medicine. NCT00472992 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.